<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000134</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-33</org_study_id>
    <secondary_id>U10EY008057</secondary_id>
    <secondary_id>U01AI027668</secondary_id>
    <nct_id>NCT00000134</nct_id>
  </id_info>
  <brief_title>Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)</brief_title>
  <acronym>CRRT</acronym>
  <official_title>Cytomegalovirus Retinitis Retreatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV
      retinitis who have been previously treated but whose retinitis either is nonresponsive or has
      relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and
      (3) combination foscarnet and ganciclovir.

      To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis:
      (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CMV retinitis is the most common intraocular infection in patients with AIDS and is estimated
      to affect 35 to 40 percent of patients with AIDS. Untreated CMV retinitis is a progressive
      disorder, the end result of which is total retinal destruction and blindness. At the time of
      this trial, drugs approved by the United States Food and Drug Administration (FDA) for the
      treatment of CMV retinitis were ganciclovir (Cytovene) and foscarnet (Foscavir). Although
      most retinitis responds well to initial therapy with systemically administered drugs, given
      enough time, nearly all patients will suffer a relapse of the retinitis. Relapsed retinitis
      generally responds to reinduction and maintenance therapy, but the interval between
      successive relapses progressively shortens. The CRRT addressed the issue of the management of
      relapsed CMV retinitis.

      The CRRT was a multicenter, randomized, controlled clinical trial comparing three regimens in
      patients with relapsed retinitis. Patients with AIDS and CMV retinitis that had relapsed or
      was nonresponsive to initial therapy were randomized to one of three regimens: (1)
      intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by
      maintenance therapy at 120 mg/kg/day; (2) intravenous ganciclovir reinduction at 5 mg/kg
      twice daily for 2 weeks followed by maintenance at 10 mg/kg/day; and (3) combination therapy,
      wherein patients continued their previous therapy and were reinduced with the second drug and
      then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5
      mg/kg/day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1992</start_date>
  <completion_date type="Actual">March 1995</completion_date>
  <primary_completion_date type="Actual">March 1995</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial</time_frame>
    <description>To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>HIV Infections</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Cytomegalovirus Retinitis</condition>
  <arm_group>
    <arm_group_label>intravenous foscarnet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous ganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
    <description>intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
    <arm_group_label>intravenous ganciclovir</arm_group_label>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>cytovene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet</intervention_name>
    <description>intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
    <arm_group_label>intravenous foscarnet</arm_group_label>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>foscavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or
        older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum
        of 28 days of previous treatment with an anti-CMV drug. Furthermore, they must have had an
        absolute neutrophil count greater than or equal to 500 cells/µL, platelet count greater
        than or equal to 20,000 cells/µL, and a serum creatinine &lt; 2.5 mg/dL in order to tolerate
        the drug regimens.

        exclusion criteria: history of intolerance to ganciclovir or foscarnet, history of therapy
        involving the combination of foscarnet and ganciclovir, unwillingness to practice
        appropriate birth control, active drug or alcohol abuse, media opacity, retinal detachment
        not scheduled for surgical repair
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.nei.nih.gov/news/pressreleases/crrtpressrelease.asp</url>
    <description>NEI Press Release-Two Drug Treatment Is Effective Against Recurrent Eye Infection In AIDS Patients</description>
  </link>
  <reference>
    <citation>Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol. 1996 Jan;114(1):23-33.</citation>
    <PMID>8540847</PMID>
  </reference>
  <reference>
    <citation>Martin BK, Kaplan Gilpin AM, Jabs DA, Wu AW; Studies of Ocular Complications of AIDS Research Group. Reliability, validity, and responsiveness of general and disease-specific quality of life measures in a clinical trial for cytomegalovirus retinitis. J Clin Epidemiol. 2001 Apr;54(4):376-86.</citation>
    <PMID>11305288</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 1999</study_first_submitted>
  <study_first_submitted_qc>September 23, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 1999</study_first_posted>
  <results_first_submitted>June 15, 2015</results_first_submitted>
  <results_first_submitted_qc>August 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2015</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Curtis Meinert</investigator_full_name>
    <investigator_title>Curtis Meinert, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>December 1992</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Foscarnet</title>
          <description>intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Ganciclovir</title>
          <description>intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
        </group>
        <group group_id="P3">
          <title>Combination Therapy</title>
          <description>combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Foscarnet</title>
          <description>intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Ganciclovir</title>
          <description>intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
        </group>
        <group group_id="B3">
          <title>Combination Therapy</title>
          <description>combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="279"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morbidity</title>
        <description>To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.</description>
        <time_frame>Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Foscarnet</title>
            <description>intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Ganciclovir</title>
            <description>intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
          </group>
          <group group_id="O3">
            <title>Combination Therapy</title>
            <description>combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity</title>
          <description>To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Foscarnet</title>
          <description>intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Ganciclovir</title>
          <description>intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day</description>
        </group>
        <group group_id="E3">
          <title>Combination Therapy</title>
          <description>combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="32" subjects_at_risk="88"/>
                <counts group_id="E2" events="95" subjects_affected="41" subjects_at_risk="93"/>
                <counts group_id="E3" events="107" subjects_affected="51" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title vocab="other">Thrombocytopenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" events="19" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" events="40" subjects_affected="15" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Curtis Meinert, PhD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-8198</phone>
      <email>cmeinert@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

